![Theresa R. Boni](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loopbaan van Theresa R. Boni
Eerdere bekende functies van Theresa R. Boni
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SURFACE ONCOLOGY, INC. | Algemeen Adviseur | 15-03-2022 | 01-11-2022 |
Bedrijfssecretaris | 15-03-2022 | 01-11-2022 | |
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Opleiding van Theresa R. Boni
Union College (New York) | Undergraduate Degree |
Boston University School of Law | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
General Counsel | 1 |
Corporate Secretary | 1 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Surface Oncology, Inc.
![]() Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
![]() Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Beurs
- Insiders
- Theresa R. Boni
- Ervaring